Search Bar & Filters
Found 199 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating new treatment approaches for advanced ovarian cancer in people whose tumors are non-HRD positive. This study aims to find out if adding sacituzumab tirumotecan sac-TMT, a targeted therapy, as maintenance treatmentwith or without bevacizumabhelps patients live longer without their cancer worsening compared to standard care. This is a phase 3 randomized study involving participants who have completed surgery and first-line platinum-based chemotherapy. Participants receive sac-TMT intravenously on days 1, 15, and 29 of every 6-week cycle until their disease worsens or they experience prohibitive side effects. Some may also receive bevacizumab intravenously on days 1 and 22 every 6 weeks for up to 22 cycles, depending on the investigators choice. The comparison group receives either bevacizumab alone on the same schedule or is observed closely without maintenance treatment. During the study, participants will have regular evaluations to monitor their cancer status and quality of life. Researchers will measure progression-free survival for up to about 49 months and assess overall survival, adverse events, treatment discontinuation, and changes in quality of life scores for up to 78 months. Participants health will be followed long-term to understand treatment effects and safety over time.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of dazodalibep in people with Sjgrens Syndrome. This phase 3 open-label study extends previous trials by continuing to monitor participants who completed 48 weeks of treatment with dazodalibep or placebo. The study is sponsored by Amgen and aims to better understand the safety profile of dazodalibep over an extended period. Participants who finished the initial 48-week trials HZNP-DAZ-301 or HZNP-DAZ-303 will receive an assigned dose of dazodalibep intravenously for an additional 132 weeks. This extension study involves a single treatment group receiving dazodalibep without placebo, focusing on ongoing treatment effects and participant safety. During the study, participants will be monitored for treatment-emergent adverse events for up to 152 weeks. Researchers will also measure the presence of anti-drug antibodies and plasma concentrations of dazodalibep for up to 132 weeks. Participants need to be available for all study visits and procedures, with safety assessments conducted regularly throughout the long-term extension period.
Actively Recruiting
This research aims to evaluate the effects of elafibranor in adults diagnosed with Primary Biliary Cholangitis PBC who also have cirrhosis, a condition where the liver develops scarring. PBC is a slowly worsening disease that damages bile ducts in the liver, causing bile acids to build up and further harm the liver. The study focuses on whether elafibranor can better prevent worsening clinical outcomes, such as disease progression leading to liver transplant or death, compared to a placebo. It also assesses the long-term safety of elafibranor and its impact on symptoms like itching and fatigue. Participants are randomly assigned to one of two groups one group takes an 80 mg tablet of elafibranor daily, and the other takes a placebo tablet that looks the same. The tablets are taken orally each morning with or without food. This double-blind study lasts up to 3.5 years for each participant, during which the effects and safety of the study drug are closely monitored. Throughout the study, participants undergo regular assessments including physical exams, vital signs checks, blood tests, liver imaging, and questionnaires about symptoms and quality of life. These evaluations happen at baseline, then every 6 to 12 months up to the end of treatment. Researchers measure various health indicators such as liver enzyme levels, bilirubin, liver stiffness, and symptom scores. Safety is monitored by tracking adverse events and changes in laboratory and clinical findings. The primary outcome is the time participants remain free from clinical events related to disease worsening over the study period.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating the safety, tolerability, how the body processes and responds to BGB-B2033, and its preliminary antitumor activity in adults with advanced or metastatic cancers including hepatocellular carcinoma, alpha-fetoprotein-producing gastric cancer, extragonadal yolk sac tumors, non-dysgerminomas, and glypican-3-positive squamous non-small cell lung cancer. The study aims to find the recommended dose for further research when BGB-B2033 is given alone or combined with tislelizumab, with or without bevacizumab. Participants will receive BGB-B2033 through intravenous infusion either alone or combined with tislelizumab and sometimes bevacizumab. The study includes several parts dose escalation and safety expansion of BGB-B2033 alone, combination treatments to determine safe doses and recommended doses for expansion, and dose expansion in specific groups including participants with hepatocellular carcinoma in Asia and the United States. During the study, participants will have regular assessments to monitor safety, side effects, how their body processes BGB-B2033, and whether their cancer responds to treatment. Researchers will track adverse events, the best dose, overall response rates, duration of response, disease control, progression-free survival, serum drug levels, and overall survival for up to about two years. Participants will be closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating sonrotoclax, alone and in combination with dexamethasone, carfilzomib, daratumumab, and pomalidomide, in patients with relapsed or refractory multiple myeloma who have a specific chromosomal translocation t1114. The study aims to assess the safety, tolerability, and effectiveness of sonrotoclax in this group. This research is sponsored by BeOne Medicines and is conducted as a Phase 1b2 interventional trial. The study includes dose-escalation and de-escalation phases to find the maximum tolerated dose of sonrotoclax with each combination. Participants may receive sonrotoclax orally every day, dexamethasone once weekly by mouth or intravenously, carfilzomib intravenously weekly, daratumumab subcutaneously weekly, or pomalidomide orally daily. There are up to seven expansion groups to further evaluate safety and effectiveness of sonrotoclax alone or combined with the other drugs. Participants will be monitored for dose-limiting toxicities and adverse events throughout the treatment periods. Researchers will assess response rates and durability of response over about four years. Blood and urine tests will measure disease markers, and organ function will be checked. Safety monitoring continues up to 30 days after last dose, and long-term outcomes like progression-free and overall survival will be evaluated. The trial will continue until November 2026.
Actively Recruiting
Researchers are studying the effects of AZD0120, an autologous dual-targeting CAR-T therapy aimed at BCMA and CD19, compared with autologous stem cell transplant ASCT in people newly diagnosed with multiple myeloma who are eligible for transplant. This open-label, randomized Phase III trial aims to measure progression-free survival and the rate of minimal residual disease negative complete response over up to 13 years. Participants are assigned to one of two treatment groups. Arm A receives lymphodepletion with cyclophosphamide and fludarabine over three days, followed by a single infusion of AZD0120 CAR-T cells, then up to two years of lenalidomide maintenance therapy. Arm B receives high-dose melphalan conditioning for 24 to 48 hours followed by ASCT and then the same lenalidomide maintenance regimen for up to two years. The study includes a long-term follow-up period lasting up to 15 years after the last AZD0120 infusion. Throughout the study, participants undergo regular monitoring, including assessments of disease progression and response according to established criteria. Researchers evaluate outcomes such as progression-free survival, complete and overall response rates, duration of response, and safety over approximately 13 years. Participants may expect study visits and evaluations aligned with treatment and follow-up schedules to track their health and treatment effects during this extended period.
1-10 of 199
1